Ying Jing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/652881/publications.pdf Version: 2024-02-01



VINC LINC

#	Article	IF	CITATIONS
1	Harnessing big data to characterize immune-related adverse events. Nature Reviews Clinical Oncology, 2022, 19, 269-280.	12.5	41
2	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
3	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer, 2021, 124, 414-424.	2.9	38
4	Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer. Journal of Urology, 2021, 206, 873-884.	0.2	20
5	Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell, 2021, 39, 1558-1559.	7.7	22
6	Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma. Journal of Medical Genetics, 2020, 57, 605-609.	1.5	13
7	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nature Communications, 2020, 11, 4946.	5.8	120
8	Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer. Oncogene, 2019, 38, 3047-3060.	2.6	6
9	Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nature Communications, 2018, 9, 215.	5.8	108
10	Hepatic SMARCA4 predicts HCC recurrence and promotes tumour cell proliferation by regulating SMAD6 expression. Cell Death and Disease, 2018, 9, 59.	2.7	26
11	Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene, 2018, 37, 3039-3044.	2.6	40
12	Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. Journal of Pathology, 2018, 244, 5-10.	2.1	3
13	Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer. Molecular Cancer Therapeutics, 2017, 16, 1739-1750.	1.9	58
14	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nature Communications, 2017, 8, 823.	5.8	53
15	Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer. Cancer Research, 2017, 77, 6551-6561.	0.4	26
16	BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics, 2016, 6, 219-230.	4.6	76
17	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. Theranostics, 2016, 6, 1232-1243.	4.6	42
18	A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Scientific Reports, 2016, 6, 31079.	1.6	18

Ying Jing

#	Article	IF	CITATIONS
19	Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget, 2016, 7, 2545-2554.	0.8	30
20	miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget, 2016, 7, 2672-2683.	0.8	68
21	Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Scientific Reports, 2015, 5, 16066.	1.6	50
22	Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis, 2015, 36, 937-945.	1.3	19
23	Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer. Tumor Biology, 2015, 36, 9753-9761.	0.8	22
24	Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology, 2014, 60, 1686-1696.	3.6	115
25	Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Research, 2014, 24, 204-217.	5.7	61
26	SERPINA5 inhibits tumor cell migration by modulating the fibronectinâ€integrin β1 signaling pathway in hepatocellular carcinoma. Molecular Oncology, 2014, 8, 366-377.	2.1	41
27	In Vitro Differentiation of Mouse Embryonic Stem Cells into Neurons of the Dorsal Forebrain. Cellular and Molecular Neurobiology, 2011, 31, 715-727.	1.7	11